[Form 4] Medtronic plc Insider Trading Activity

Rhea-AI Filing Summary

William R. Jellison, a director of Medtronic plc (MDT), reported two open-market purchases of ordinary shares. He acquired 2,500 shares on 08/22/2025 at $92.73 per share and 2,500 shares on 08/25/2025 at $92.37 per share, bringing his reported direct beneficial ownership to 5,000 shares. The filing notes the shares are held in a joint account with his spouse. The Form 4 was executed by an attorney-in-fact on 08/25/2025. No derivative transactions or dispositions are reported in this filing.

Positive

• Director purchased additional common stock, acquiring 5,000 shares in two transactions and increasing reported direct ownership
• Transactions are disclosed with explicit prices and dates, supporting transparency under Section 16 reporting requirements

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Director made modest open-market purchases totaling 5,000 shares, indicating a routine insider buy.

These purchases are disclosed under Section 16 reporting rules and reflect direct acquisitions rather than derivative activity. The combined purchase amount (~$462,500) is a straightforward insider buy and does not by itself constitute a material change to ownership or control. The filing also documents joint holding with a spouse and was signed by an attorney-in-fact, which are standard procedural details. Governance implications are limited given the small size relative to a large-cap issuer.

Securities Analyst

TL;DR: Two purchase transactions at roughly $92.7 and $92.4 increased director's direct holdings to 5,000 shares.

From a market-data perspective this Form 4 reports routine, small-scale purchases by an insider. The transactions are recorded with explicit prices and dates, with no sales or option exercises. For investors tracking insider activity, this is factual confirmation of buy-side activity but lacks scale to signal a meaningful shift in insider conviction or ownership concentration.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jellison William R

(Last) (First) (Middle)

C/O MEDTRONIC

710 MEDTRONIC PARKWAY

(Street)

MINNEAPOLIS MN 55432

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medtronic plc [ MDT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/22/2025		P		2,500	A	$92.73	2,500	D
Ordinary Shares	08/25/2025		P		2,500	A	$92.37	5,000(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares are held in joint account with spouse.

Remarks:

	/s/ Patricia Walesiewicz, attorney-in-fact	08/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What trades did Medtronic director William R. Jellison report on Form 4 (MDT)?

He reported purchasing 2,500 shares on 08/22/2025 at $92.73 and 2,500 shares on 08/25/2025 at $92.37, totaling 5,000 shares.

How many shares does William R. Jellison own after the reported transactions?

The filing shows 5,000 shares beneficially owned following the reported purchases.

Were any derivative securities or sales reported in this Form 4 for MDT?

No. The filing shows only non-derivative purchases; there are no derivative transactions or dispositions reported.

Are the shares held directly or indirectly according to the filing?

The filing indicates direct (D) beneficial ownership, with a note that shares are held in a joint account with his spouse.

Who signed the Form 4 and when was it executed?

The Form 4 was executed by Patricia Walesiewicz, attorney-in-fact on 08/25/2025.